RLAY (Relay Therapeutics) Total Debt per Share: $0.14 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RLAY Relay Therapeutics Inc RLAY
53 GF Score
Price $20.07
GF Value $3.80
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Relay Therapeutics Total Debt per Share?

Relay Therapeutics RLAY -0.05% 53 Total Debt per Share is $0.14 as of Jun. 2026. GuruFocus rates RLAY with a GF Score™ of 53/100 and a GF Value™ of $3.80 (Significantly Overvalued). The stock has 7 warning signs investors should review.

$0.14 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Relay Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 was $0.14.

Relay Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Relay Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Relay Therapeutics Total Debt per Share Chart

Relay Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
Get a 7-Day Free Trial 0.21 0.48 0.42 0.29 0.19

Relay Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.19 0.19 0.17 0.14
RLAY
53GF Score
Relay Therapeutics Inc RLAY
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Relay Therapeutics Total Debt per Share Calculation

Relay Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(28.69+3.77)/173.87
=0.19

Relay Therapeutics's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(26.64+4.01)/218.53
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.14 mean?
Relay Therapeutics (RLAY) has a Total Debt per Share of $0.14 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Relay Therapeutics and its competitors.
Is Relay Therapeutics' Total Debt per Share too high?
Relay Therapeutics' current Total Debt per Share is $0.14. Overall, Relay Therapeutics has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Relay Therapeutics' Total Debt per Share compare to CELC and VKTX?
Relay Therapeutics' Total Debt per Share of $0.14 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Relay Therapeutics and its competitors. Relay Therapeutics's current Total Debt per Share is $0.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Relay Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Relay Therapeutics (RLAY) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.80, compared to a current price of $20.07 — trading 428.2% above its estimated fair value. The current Total Debt per Share is $0.14. Relay Therapeutics' overall GF Score™ is 53/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Relay Therapeutics (RLAY), the current Total Debt per Share is $0.14 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Relay Therapeutics (RLAY) Overvalued in 2026?

Based on GuruFocus' analysis, Relay Therapeutics stock appears to be overvalued. The current stock price of $20.07 is trading 428.2% above its estimated GF Value™ of $3.80. GuruFocus considers Relay Therapeutics to be Significantly Overvalued.

Key valuation signals for RLAY:

  • Total Debt per Share: $0.14
  • GF Value™: $3.80 vs. price of $20.07 (428.2% above fair value)
  • GF Score™: 53/100 with 7 warning signs

No single metric tells the full story. See the RLAY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Relay Therapeutics Business Description

Address 60 Hampshire Street, Cambridge, MA, USA, 02139
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.
53GF Score

Get the complete analysis for RLAY

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.07
Price
$3.80
GF Value